Glivec

• Patent row: High Court refuses interim relief to US drug firm Merck

  Justice Rajiv Sahai Endlaw dismissed the interim application of the multinational pharma major that the Mumbai-based firm be restrained from manufacturing and selling the anti-diabetes medicines on the grounds that the salt used in the drugs were not of generic nature.

• Supreme Court order on Novartis will impact investment in India: USIBC

  "Innovation requires the reward and protection of intellectual property. We are certain India's leadership understands this, and that creating and maintaining an environment that inspires and enables innovation is in India's ultimate, long-term interest. Such an environment is crucial if India is to attract investment in this or other highly comple...

• US trade office reviewing Supreme Court's Novartis patent ruling

  "We are ... reviewing the Court's order. We look forward to continued engagement and successful collaboration with India on these issues," said Andrea Mead, a spokeswoman for the US Trade Representative's office.

• Big Pharma down, not out, after Novartis patent blow

  Stung by a landmark patent defeat, Western drug-makers will be wary about launching new products in India, but they cannot afford to quit a country tipped to be the world's eighth largest market for medicines by 2016.

• Novartis loses landmark India patent case on Glivec

  The Supreme Court dismissed Swiss drug-maker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.

• Post Supreme Court verdict, Novartis to invest in India 'cautiously'

  Swiss drugmaker Novartis AG will continue to invest in India, the vice chairman and managing director of the company said today after the Supreme Court dismissed the pharmaceutical major's plea for patent protection of its cancer drug Glivec.

• Novartis on patent setback: Will continue to invest in India, but cautiously

  Novartis India Limited, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the country's top court rejected its plea for patent protection of its drug Glivec.

• Novartis judgement: What it means for you

  The Supreme Court on Monday rejected Swiss drugmaker Novartis AG's plea for patent protection of its cancer drug Glivec. The Supreme Court's decision comes after a legal battle that began when Novartis was denied a patent for Glivec in 2006.

• Novartis: Will continue with our investments in India, although catiously

  The Supreme Court today rejected Swiss drugmaker Novartis AG's plea for a patent protection of its cancer drug Glivec, a move likely to boost the prospects of Indian pharmaceutical firms over foreign ones.

• Supreme Court's decision on Novartis AG to benefit poor patients, say pharma companies

  Poor patients will have easier access to quality medicines with the Supreme Court rejecting Swiss firm Novartis' patent plea for its cancer drug Glivec, according to domestic manufacturers.

• Supreme Court backs generics in Novartis drug patent ruling

  India's Supreme Court rejected Monday a patent bid by Swiss drug giant Novartis in a landmark ruling that activists say will protect access to cheap generic drugs and save lives in developing nations.

• Supreme Court rejects Novartis AG's plea for cancer drug patent: Read full verdict

  The Supreme Court has dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales. Here is the copy of the full verdict:

• Novartis AG's plea for Glivec patent dismissed by Supreme Court

  The Supreme Court dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.

• Novartis shares fall 7% after Supreme Court rejects patent for cancer drug

  Shares in drug maker Novartis AG fell sharply after the Supreme Court ruled that the Swiss giant's cancer treatment Glivec does not deserve a patent in India. The ruling was being closely watched by global drugmakers who have been battered by recent intellectual property decisions in India.

• Supreme Court rejects patent for cancer drug from pharma giant Novartis

  The Supreme Court has dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales.